Report: Elon Musk’s Alleged Drug Use Intensified During $270M Pro-Trump Push, Sparking Board Concerns
A new report from The New York Times alleges that Elon Musk’s consumption of drugs, including ketamine and Adderall, escalated significantly beyond recreational use during the 2024 presidential campaign, a period in which he reportedly contributed around $270 million to aid Donald Trump’s election efforts.
Sources close to the situation told The Times that Musk’s drug use intensified over the past year. He was reportedly seen carrying a “medication box” containing approximately 20 pills, including Adderall. The report further claims his use of ketamine was so frequent that it allegedly led to bladder-related issues.
Musk’s reported affinity for substances like ketamine, psychedelic mushrooms, and ecstasy has been previously documented and is said to be a growing concern for board members at his major companies, notably Tesla and SpaceX. The latter, a significant U.S. government contractor, is mandated to maintain a drug-free workplace. According to The Times, Musk may have received advance warnings about drug tests, potentially circumventing these requirements.
While the report details these allegations, it stops short of definitively linking his reported drug-taking to several instances of erratic public behavior. These include publicly insulting cabinet members, making a gesture resembling a Nazi salute, and instances of jumbled speech during earnings calls and other public appearances.
The New York Times also highlights that Musk’s deepening engagement with right-wing political ideologies coincided with personal challenges, including a custody dispute with the musician Grimes over their five-year-old child, known as X.
In a recent development, Musk announced this week his intention to step back from active political involvement and refocus on his business ventures. This announcement comes just ahead of a scheduled joint press conference with President Trump, slated for Friday afternoon. The revelations add another layer of complexity to the public persona of the billionaire entrepreneur, raising questions about corporate governance and personal conduct at the helm of some of the world’s most influential companies.
